IBMX
PDE inhibitor (pan-spec) / Pan-specific inhibitor of phosphodiesterases (IC50=2-50 µM). Inhibition of PDEs leads to increased concentration of intracellular cAMP which activates PKA2. Does not inhibit PDE8 or PDE93. Weak adenosine receptor antagonist4.
Biochemicals & reagents
28822-58-4
3-Isobutyl-1-methylxanthine
1) Beavo et al. (1970), Effects of xanthine derivatives on lipolysis and on adenosine 3’,5’-monophosphate phosphodiesterase activity; Mol. Pharmacol., 6 597 / 2) Tomes et al. (1993), Isobutylmethylxanthine and other classical cyclic nucleotide phosphodiesterase inhibitors affect cAMP-dependent protein kinase activity; Cell Signal., 5 615 / 3) Soderling et al. (2000), Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions; Curr. Opin. Cell Biol., 12 174 / 4) Daly et al. (1987), Adenosine receptors: development of selective agonists and antagonists; Prog. Clin. Biol. Res., 230 41
RT
TARGET: PDE (Phosphodiesterase); GPCR -- PATHWAY: cAMP / cGMP signaling; Lipid signaling; TNF; Cytokine; Apoptosis inhibitor -- RESEARCH AREA: Neuroscience; Immunology; Stem cells; Cell death -- DISEASE AREA: Addiction; Inflammation